دورية أكاديمية
Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study
| العنوان: | Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study |
|---|---|
| المؤلفون: | Weber, Catherine, Merminod, Thierry, Herrmann, François, Zulian, Gilbert |
| المصدر: | ISSN: 0941-4355 ; Supportive care in cancer, vol. 16, no. 7 (2008) p. 847-852. |
| سنة النشر: | 2008 |
| المجموعة: | Université de Genève: Archive ouverte UNIGE |
| مصطلحات موضوعية: | info:eu-repo/classification/ddc/618.97, Aged, Aged 80 and over, Anticoagulants/therapeutic use, Female, Humans, Male, Middle Aged, Nadroparin/therapeutic use, Neoplasms/complications/mortality/pathology/physiopathology, Palliative Care/methods, Prospective Studies, Survival, Venous Thromboembolism/prevention & control/ultrasonography |
| الوصف: | GOALS: The objective of this study was to determine utility of prophylactic anti-coagulation in cancer patients hospitalised for palliative care in a specialised centre. MATERIALS AND METHODS: Prospective 1:1 open randomised study was designed. Twenty patients aged 55 to 88 years with advanced cancer and an estimated life expectancy of less than 6 months were assigned to either receive treatment with 2,850/3,800 U (<70/>70 kg) of daily subcutaneous nadroparin or no treatment. Suspicion of venous thrombo-embolism (deep vein thrombosis and pulmonary embolism) was confirmed by echo-Doppler examination of the lower limbs and/or by spiral computed tomography scan of the lungs. Bleeding episodes were recorded. Platelet count was measured on days 7 and 14. Survival time from study entry was determined. MAIN RESULTS: One venous thrombo-embolism and one major bleeding occurred in the group receiving nadroparin, whereas two minor bleedings occurred in the control group. At 3 months, nine of ten participants had died in the control group vs five of ten in the group receiving nadroparin (P = 0.141). Five participants could be discharged home (P = 0.141). CONCLUSIONS: Decision to administer prophylactic nadroparin in hospitalised cancer patients under palliative care remains a challenge. Better mobility score at admission and the likelihood to be discharged home may be useful for practical purposes. The observation of a potential influence of prophylactic nadroparin on survival deserves further studies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/17940809; https://archive-ouverte.unige.ch/unige:822Test; unige:822 |
| الإتاحة: | https://doi.org/10.1007/s00520-007-0339-3Test https://archive-ouverte.unige.ch/unige:822Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.47034152 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |